Top Markets
Coin of the day
Miravant Medical Technologies Inc. Miravant Medical Technologies Inc.

Miravant Medical Technologies Inc.

MRVT
Rangering i aksjer #42699
Miravant Medical Technologies Inc. operates as a specialized firm dedicated to... Miravant Medical Technologies Inc. operates as a specialized firm dedicated to pharmaceutical research and development. A cornerstone of its work involves PhotoPoint, an innovative photodynamic therapy designed to eradicate cancerous cells when exposed to light. Furthermore, the company manufactures the essential light-generating and light-delivery devices required for this treatment. Miravant's product pipeline includes several therapeutic agents: PHOTREX, which is aimed at treating wet age-related macular degeneration (AMD); MV9411, a photoreactive compound developed for managing plaque psoriasis; MV0633, which targets conditions like atherosclerosis, vulnerable atherosclerotic plaque, and restenosis; MV2101, designed to address vascular access graft disease in hemodialysis patients; and MV6401, a treatment under development for solid tumors. The organization, originally established as PDT, Inc., officially adopted its current name, Miravant Medical Technologies Inc., in September of 1997. Founded in 1989, it maintains its corporate headquarters in Santa Barbara, California.
Aksjekurs
$0.00001
Sist synkronisert: 2025-06-16
Markedsverdi
$352.62
Endring (1 dag)
-99.67%
Endring (1 år)
0.00%
Land
US
Handel Miravant Medical Technologies Inc. (MRVT)

Kategori

Inntekter for Miravant Medical Technologies Inc. (MRVT)
Inntekter i 2026 TTM: 0
Ifølge Miravant Medical Technologies Inc. sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Miravant Medical Technologies Inc. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter